Literature DB >> 21773953

Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pN0 gastric cancer.

Yan-Feng Liu1, Sen Guo, Rui Zhao, Yue-Guang Chen, Xian-Qiang Wang, Ke-Sen Xu.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 play important roles in tumor angiogenesis, development, and progression. This study investigates the expression of VEGF combined with MMP-9, their correlation with clinical characteristics, and their effect on the prognosis for patients with pN0 gastric cancer after curative surgery.
METHODS: A total of 55 patients were enrolled in the study. They were analyzed by immunohistochemistry, and their correlation with clinical characteristics was then investigated. Their relations and the survival time of patients were retrospectively analyzed.
RESULTS: VEGF and MMP-9 were positively expressed in 24 (43.6%) and 16 (29.1%) patients, respectively, and had a positive correlation (r = 0.324, p = 0.016) in the Spearman rank correlation analysis. Univariate analysis showed that VEGF, MMP-9 expression, vascular invasion, T stage, and tumor size were associated with tumor recurrence as well as the disease-specific (DSS) and overall (OS) survival rates. Patients with positive VEGF expression showed significantly higher recurrence and poorer DSS and OS rates compared with those with negative VEGF expression. Multivariate analysis showed that VEGF expression, vascular invasion, T stage (serosal invasion), and tumor size were significant independent prognostic factors for tumor recurrence, DSS, and OS in patients with pN0 gastric cancer with the exception that T stage was not for DSS.
CONCLUSIONS: VEGF expression, vascular invasion, T stage (serosal invasion), and tumor size can be used as valuable prognosticators in predicting tumor recurrence and prognosis for patients with pN0 gastric cancer after curative surgery. VEGF may have a synergistic effect with MMP-9 during tumor angiogenesis, development, and progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21773953     DOI: 10.1007/s00268-011-1192-6

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  37 in total

Review 1.  Clinicopathologic studies of gastric carcinoma.

Authors:  M Mori; K Sugimachi
Journal:  Semin Surg Oncol       Date:  1990

2.  High expressions of CD105 and VEGF in early oral cancer predict potential cervical metastasis.

Authors:  Chih-Yen Chien; Chih-Ying Su; Chung-Feng Hwang; Hui-Ching Chuang; Ching-Mei Chen; Chao-Cheng Huang
Journal:  J Surg Oncol       Date:  2006-10-01       Impact factor: 3.454

3.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

4.  Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk.

Authors:  Shigeto Ogura; Takeshi Ohdaira; Yasuo Hozumi; Yawara Omoto; Hideo Nagai
Journal:  J Surg Oncol       Date:  2007-07-01       Impact factor: 3.454

5.  Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer.

Authors:  Li Hao; Chunhui Zhang; Yuhua Qiu; Liang Wang; Yunbao Luo; Min Jin; Yi Zhang; Taylor B Guo; Kouji Matsushima; Yanyun Zhang
Journal:  Cancer Lett       Date:  2007-02-16       Impact factor: 8.679

6.  Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants.

Authors:  A Janowska-Wieczorek; M Majka; L Marquez-Curtis; J A Wertheim; A R Turner; M Z Ratajczak
Journal:  Leukemia       Date:  2002-06       Impact factor: 11.528

7.  Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.

Authors:  László Herszényi; Ferenc Sipos; Orsolya Galamb; Norbert Solymosi; István Hritz; Pál Miheller; Lajos Berczi; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

8.  Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Authors:  Dorina Belotti; Paola Paganoni; Luigi Manenti; Angela Garofalo; Sergio Marchini; Giulia Taraboletti; Raffaella Giavazzi
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

9.  Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer.

Authors:  K Maeda; S M Kang; N Onoda; M Ogawa; T Sawada; B Nakata; Y Kato; Y S Chung; M Sowa
Journal:  Oncology       Date:  1998 Nov-Dec       Impact factor: 2.935

10.  Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.

Authors:  Melanie M L Green; Crispin T Hiley; Jonathan H Shanks; Ian C Bottomley; Catharine M L West; Richard A Cowan; Ian J Stratford
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-01-01       Impact factor: 7.038

View more
  10 in total

1.  Targeting angiogenesis in gastroesophageal cancer: industry-sponsored trials are not the answer.

Authors:  Sarah K Thompson
Journal:  World J Surg       Date:  2012-01       Impact factor: 3.352

2.  Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis.

Authors:  Ling Peng; Ping Zhan; Yun Zhou; Weijia Fang; Peng Zhao; Yulong Zheng; Nong Xu
Journal:  Mol Biol Rep       Date:  2012-06-23       Impact factor: 2.316

3.  Occult Tumour Cells in Lymph Nodes from Gastric Cancer Patients: Should Isolated Tumour Cells Also Be Considered?

Authors:  A Tavares; X Wen; J Maciel; F Carneiro; M Dinis-Ribeiro
Journal:  Ann Surg Oncol       Date:  2020-05-04       Impact factor: 5.344

4.  Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.

Authors:  Lorenzo Fornaro; Gianna Musettini; Paola Orlandi; Irene Pecora; Caterina Vivaldi; Marta Banchi; Francesca Salani; Elisabetta Fini; Valentina Massa; Silvia Catanese; Federico Cucchiara; Monica Lencioni; Gianluca Masi; Enrico Vasile; Guido Bocci
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

5.  Clinical significance of integrin αvβ6 expression effects on gastric carcinoma invasiveness and progression via cancer-associated fibroblasts.

Authors:  Zhuonan Zhuang; Ruiling Zhou; Xiaozhou Xu; Tian Tian; Yi Liu; Yanfeng Liu; Peilong Lian; Jiayong Wang; Kesen Xu
Journal:  Med Oncol       Date:  2013-05-15       Impact factor: 3.064

6.  Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Yang Li; Zhi Wang
Journal:  Tumour Biol       Date:  2014-03

7.  Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

Authors:  Johanna Bendell; Sunil Sharma; Manish R Patel; Kevin S Windsor; Zev A Wainberg; Michael Gordon; Jorge Chaves; Jordan Berlin; Carrie Baker Brachmann; Marianna Zavodovskaya; JieJane Liu; Dung Thai; Pankaj Bhargava; Manish A Shah; Saad A Khan; Alexander Starodub
Journal:  Oncologist       Date:  2020-09-17

8.  Aberrant CCR4 expression is involved in tumor invasion of lymph node-negative human gastric cancer.

Authors:  Yongmei Yang; Lutao Du; Xiaoyun Yang; Ailin Qu; Xin Zhang; Chengjun Zhou; Chuanxin Wang
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

9.  Apatinib Inhibits the Invasion and Metastasis of Liver Cancer Cells by Downregulating MMP-Related Proteins via Regulation of the NF-κB Signaling Pathway.

Authors:  Xiaoxiao He; Zaozao Huang; Ping Liu; Qiuting Li; Mengmeng Wang; Mengjun Qiu; Zhifan Xiong; Shengli Yang
Journal:  Biomed Res Int       Date:  2020-06-19       Impact factor: 3.411

10.  Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.

Authors:  Akie Kimura Yoshikawa; Kensei Yamaguchi; Kei Muro; Atsuo Takashima; Takashi Ichimura; Daisuke Sakai; Shigenori Kadowaki; Keisho Chin; Toshihiro Kudo; Seiichiro Mitani; Shigehisa Kitano; Dung Thai; Marianna Zavodovskaya; JieJane Liu; Narikazu Boku; Taroh Satoh
Journal:  J Immunother Cancer       Date:  2022-01       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.